Table 1.
Clinical characteristics, treatment and outcomes of COVID-19 total patients and subdivided in with or without myocardial injury.
|
Total (n = 254) |
Myocardial injury (+) (n = 73) |
Myocardial injury (−) (n = 181) |
p value | |
|---|---|---|---|---|
| Age (years) | 53.8 SD 12.7 | 54.3 SD 10.7 | 53.6 SD 13.1 | NS |
| Male n (%) Female n (%) |
167 (65.7) 87 (34.3) |
47 (64.5) 26 (35.5) |
120 (66.2) 61 (33.8) |
NS |
| BMI (Kg/Mm2) | 29.8 SD 7.7 | 29.5 SD 9.0 | 26.5 SD 9.0 | 0.014 |
|
Comorbidities n (%) Coronary Heart Disease Autoimmune Diseases COPD Overweight or Obesity Smoking Hypertension Diabetes mellitus Chronic Kidney Disease ACE2i or ARBs treatment |
14 (5.5) 6 (2.4) 1 (0.4) 158 (62.2) 38 (15.0) 90 (35.4) 80 (31.5) 2 (0.8) 70 (27.6) |
5 (6.8) 1 (1.4) 0 (0.0) 60 (82.2) 14 (19.2) 34 (45.3) 27 (37.0) 1 (1.4) 20 (27.4) |
9 (5.0) 5 (2.8) 1 (0.6) 98 (54.1) 24 (13.2) 56 (31.0) 53 (29.3) 1 (0.6) 50 (27.6) |
NS NS NS 0.001 NS 0.014 NS NS NS |
|
Symptoms n (%) Fever Odynophagia Dyspnea Headache Cough Diarrhea Myalgia or Arthralgia Tiredness Rhinorrhea |
220 (86.6) 130 (51.2) 220 (86.6) 126 (49.6) 211 (83.0) 52 (20.5) 203 (79.9) 220 (86.6) 52 (20.5) |
54 (74.0) 30 (41.1) 70 (95.9) 23 (31.5) 54 (74.0) 14 (19.2) 57 (78.0) 62 (84.9) 7 (9.6) |
166 (92.8) 100 (55.2) 150 (82.9) 103 (56.9) 157 (86.7) 38 (20.9) 146 (80.6) 158 (87.3) 45 (24.8) |
0.004 NS 0.020 0.001 NS NS NS NS 0.004 |
|
Complications n (%) Acute Kidney Injury Renal Replacement Therapy ARSD Septic Shock Arrhythmias (ST, SB, AF) (n%) |
64 (25.2) 23 (9.0) 133 (52.3) 82 (32.2) 20 (7.9) |
36 (49.3) 11 (15.0) 49 (67.1) 50 (68.5) 20 (27.4) |
27 (14.9) 12 (6.6) 84 (46.4) 32 (17.6) 0 (0%) |
<0.001 0.003 0.009 <0.001 <0.001 |
| Hospitalization days Mechanical Ventilation (%) Mechanical Ventilation days |
12.0 SD 3.0 133 (52.3) 9.0 SD 1.5 |
11.5 SD 2.8 49 (67.1) 10 SD 1.5 |
12.0 SD 3.0 84 (46.4) 9.0 SD 1.5 |
NS <0.001 NS |
|
Treatment n (%) HCQ + Azithromycin High dose Steroids VTE prophylaxis |
139 (54.7) 105 (41.3) 73 (28.7) |
50 (68.5) 49 (67.1) 50 (68.5) |
89 (49.1) 56 (30.9) 85 (46.9) |
<0.001 <0.001 <0.001 |
| Death n (%) | 89 (35.0) | 46 (63.0) | 43(23.7) | <0.001 |
Each value represents the mean ± SD or the number (%). p < 0.05 was considered statistically significant. Chronic obstructive pulmonary disease (COPD), Angiotensin-converting enzyme 2 inhibitors (ACE2i), Angiotensin II receptor blockers (ARBs), acute respiratory distress syndrome (ARDS), Sinus tachycardia (ST), Sinus bradycardia (SB), Atrial fibrillation (AF), Hydroxychloroquine (HCQ), venous thromboembolism (VTE).